Related party disclosures |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Related party disclosures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Related party disclosures |
Note 9 — Related party disclosures
Adaptimmune and Immunocore Limited (“Immunocore”) have a shared history, some overlap in our board membership and substantial overlap in our shareholder base. The Company has entered into several agreements regarding the shared use of certain services including licensing and research collaboration. Since inception, we have maintained separate financial statements and we believe our agreements are on an arm’s length basis. Accordingly, we do not believe our relationship with Immunocore has had or will have a significant impact on our financial statements.
During the period, Immunocore has invoiced the Company in respect of the transitional services agreement, property rent and joint patent costs. The Company has invoiced Immunocore in respect of the transitional services agreement.
Transactions entered into in the three months to March 31, 2016 and 2015 are as follows (in thousands):
Trading balances outstanding as of March 31, 2016 and December 31, 2015 are as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||